BioSpace News Archive

Mentice AB announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Elisabet Lund.

Immunovia will publish the company’s interim report for the period January 1 - March 31, 2021 on Wednesday, April 28, 2021 at 16:00 CET.

Rosacea sufferers join forces this Rosacea Awareness Month to bravely share the personal impact essential COVID-19 mask-wearing has on their skin condition

EdiGene, Inc., announced the successful completion of an RMB 400 million Series B Plus financing. Loyal Valley Capital led the round and other new investors included BioTrack Capital and Sherpa Healthcare Partners, along with continued support by existing investors including IDG Capital, Lilly Asia Venture, 3H Health Investment, Huagai Capital, Sequoia Capital China, Alwin Capital and Kunlun Capital.

A new collaboration will help oncologists learn whether Black and white cancer patients respond differently to a game-changing immunotherapy treatment, and seeks to improve the safety and effectiveness of these newer drugs in diverse populations.

Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, announced that the U.S. Food and Drug Administration has approved its Investigational Device Exemption application to conduct a U.S. trial for the Contour Neurovascular System™, indicated for the treatment of intracranial aneurysms.

--$560 million primary global fund that will focus on creating 20 biotech startups-- --$140 million companion fund to boost selected early high-performers-- --$250 million opportunity fund for later-stage rounds--

Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a conference call and webcast to discuss its first quarter 2021 financial results on Wednesday, April 28, 2021 at 4:30 p.m. ET.

Cerevel Therapeutics , a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Abraham N. Ceesay to the newly-created role of president, effective May 3, 2021. Mr. Ceesay brings nearly two decades of healthcare experience leading operations at a number of biopharmaceutical companies, serving most recently as chief executive officer at Tiburio Therapeutics

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will participate in a virtual panel discussion at the Sachs 4 th Annual Neuroscience Innovation Forum.